Literature DB >> 18634784

A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images.

Heping Xu1, Philippe Koch, Mei Chen, Annie Lau, Delyth M Reid, John V Forrester.   

Abstract

Experimental autoimmune uveoretinitis (EAU), a widely used animal model of human posterior/pan-uveitis, is extremely valuable in allowing understanding of the pathogenesis of uveitis as well as in developing new treatments. Depending on the animal strain and immunization protocol used, the clinical course of EAU can be acute, severe and involving the anterior and posterior part of the eye, or chronic, mild and involving only the posterior part of the eye. Clinical signs of EAU can be examined by bio-microscopy. Using appropriate criteria EAU can be quantitatively evaluated clinically in living animals. However, correlation of research within different laboratories is difficult since clinical grading systems are subjective and susceptible to considerable variability. In this study, we have developed a recordable, image-based clinical grading system for the chronic models of EAU. Fundus images were taken from EAU mice using an endoscopic imaging system. Fundus changes were classified as (1) inflammatory changes (including optic disc inflammation, vasculitis and retinal tissue inflammation) and (2) retinal structural damage. Each element was scored separately based on the severity of the lesions, and the average score of the three inflammatory elements was used as the overall EAU clinical inflammation grade of the eye. The validity and reproducibility of the grading system was tested using a set of images scored independently in a masked manner by 5 individuals. The grading system proved robust, easy to use and reliable. We offer this image-based EAU clinical grading system as a useful quantitative evaluation method for clinical grading of the severity of inflammation in the chronic EAU model, in which the inflammation can be mild and mainly involves posterior part of the eye.

Entities:  

Mesh:

Year:  2008        PMID: 18634784     DOI: 10.1016/j.exer.2008.06.012

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  70 in total

1.  Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms.

Authors:  Hyun-Mee Oh; Cheng-Rong Yu; Yongjun Lee; Chi-Chao Chan; Arvydas Maminishkis; Charles E Egwuagu
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

2.  Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis.

Authors:  T K Khera; D A Copland; J Boldison; P J P Lait; D E Szymkowski; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

3.  Mincle Activation and the Syk/Card9 Signaling Axis Are Central to the Development of Autoimmune Disease of the Eye.

Authors:  Ellen J Lee; Brieanna R Brown; Emily E Vance; Paige E Snow; Phyllis B Silver; David Heinrichs; Xin Lin; Yoichiro Iwakura; Christine A Wells; Rachel R Caspi; Holly L Rosenzweig
Journal:  J Immunol       Date:  2016-02-26       Impact factor: 5.422

4.  AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells.

Authors:  So Jin Bing; Itay Shemesh; Wai Po Chong; Reiko Horai; Yingyos Jittayasothorn; Phyllis B Silver; Benjamin Sredni; Rachel R Caspi
Journal:  J Autoimmun       Date:  2019-03-08       Impact factor: 7.094

5.  MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis.

Authors:  Deborah A Lipski; Rémi Dewispelaere; Vincent Foucart; Laure E Caspers; Matthieu Defrance; Catherine Bruyns; François Willermain
Journal:  J Neuroinflammation       Date:  2017-07-18       Impact factor: 8.322

6.  LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity.

Authors:  Irina Proekt; Corey N Miller; Marion Jeanne; Kayla J Fasano; James J Moon; Clifford A Lowell; Douglas B Gould; Mark S Anderson; Anthony L DeFranco
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

7.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

8.  A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis.

Authors:  Joanne Boldison; Tarnjit K Khera; David A Copland; Madeleine L Stimpson; Gemma L Crawford; Andrew D Dick; Lindsay B Nicholson
Journal:  Immunology       Date:  2015-08-11       Impact factor: 7.397

9.  Aquaporin expression in blood-retinal barrier cells during experimental autoimmune uveitis.

Authors:  Elie Motulsky; Philippe Koch; Sarah Janssens; Maité Liénart; Anne-Marie Vanbellinghen; Nargis Bolaky; Chi-Chao Chan; Laure Caspers; Maria-Dolores Martin-Martinez; Heping Xu; Christine Delporte; François Willermain
Journal:  Mol Vis       Date:  2010-04-03       Impact factor: 2.367

10.  STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis.

Authors:  Thelma Escobar; Cheng-Rong Yu; Stefan A Muljo; Charles E Egwuagu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.